In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Blueberry Extract Boosts Cancer Treatment Efficacy, Therapeutic Solutions Says

Executive Summary

Therapeutic Solutions says animal study data show synergy in use of NanoStilbene, its proprietary formulation of pterostilbene, together with anti-CTLA4 antibody, "the mouse equivalent" of ipilimumab, an immunotherapeutic in the "checkpoint inhibitors" family of drugs. It also notes early results of clinical trial with cancer patients suggesting NanoStilbene efficacy in increased activity of immune system "natural killer" cells and enhanced production of interferon gamma, a protein associated with cancer growth suppression.


Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts